Europe Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Inhaled Nitric Oxide Market
The Europe Inhaled Nitric Oxide Market would witness market growth of 7.4% CAGR during the forecast period (2020-2026). Nitric oxide is a gas form of the chemical molecule, which is utilized to cure newborn babies with serious breathing problems related to narrow blood vessels in the lungs.
It helps in relaxing the muscle while broadening (dilate) blood vessels in the lungs. Nitric oxide is majorly utilized along with a breathing machine like a ventilator. The increasing prevalence of respiratory diseases and the continuing research & development activities regarding the usage of inhaled nitric oxide are among the factors that will drive the growth of the Inhaled nitric oxide market.
There are many studies that suggested that Nitric Oxide can be applied to various diseases. For example, studies stated that inhaled NO is a secure and efficient agent to identify the vasodilatory capability of the pulmonary vascular bed. At present, many incidents also suggest that inhaled nitric oxide enhances oxygenation & reduces the integrated results of death or needs for extracorporeal membrane oxygenation in newborn babies of more than 35 weeks’ gestational age at birth. Due to the aforementioned factors, the market is estimated to witness a significant growth rate during the forecast period.
The global inhaled nitric oxide market is expected to increase over the forecast period due to the increasing prevalence of respiratory diseases, the increasing number of breathing problems in infants, and the initiatives by the FDA to motivate clinical use of inhaled nitric oxide. Additionally, technological improvements in inhaled nitric oxide and the latest product introduced by the companies operating in the market are anticipated to offer lucrative opportunities over the forecast period.
Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Acute Respiratory Distress Syndrome (ARDS) Market by Country in 2019, growing at a CAGR of 7.9 % during the forecast period. The UK market is exhibiting a CAGR of 7.6% during (2020 - 2026). Additionally, The France market is poised to grow at a CAGR of 10% during (2020 - 2026).
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.
Scope of the Study
Market Segments Covered in the Report:
- Neonatal Respiratory Treatment
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Other Applications
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Getinge AB
- Merck Group
- Halma PLC
- Linde PLC (Praxair, Inc.)
- Air Liquide S.A.
- Beyond Air, Inc.
- Mallinckrodt PLC (International Minerals and Chemical Corporation)
- VERO Biotech LLC
- Nu-Med Plus, Inc.
- Novoteris, LLC
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free